These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

48 related articles for article (PubMed ID: 12513962)

  • 21. Does positron emission tomography/computed tomography change management in colorectal cancer?
    Falconer R; Connor S; Balasingam A; Eglinton T
    ANZ J Surg; 2018 Apr; 88(4):E248-E251. PubMed ID: 27788564
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effect of PET-CT on disease recurrence and management in patients with potentially resectable colorectal cancer liver metastases. Long-term results of a randomized controlled trial.
    Serrano PE; Gu CS; Moulton CA; Husien M; Jalink D; Martel G; Tsang ME; Hallet J; McAlister V; Gallinger S; Levine M
    J Surg Oncol; 2020 May; 121(6):1001-1006. PubMed ID: 32034769
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of whole-body positron emission tomography with [18F]fluorodeoxyglucose in identifying operable colorectal cancer metastases to the liver.
    Lai DT; Fulham M; Stephen MS; Chu KM; Solomon M; Thompson JF; Sheldon DM; Storey DW
    Arch Surg; 1996 Jul; 131(7):703-7. PubMed ID: 8678767
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Is (18)F-fluorodeoxyglucose positron emission tomography in recurrent colorectal cancer a contribution to surgical decision making?
    Staib L; Schirrmeister H; Reske SN; Beger HG
    Am J Surg; 2000 Jul; 180(1):1-5. PubMed ID: 11036130
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Assessment of tumor recurrence in patients with colorectal cancer and elevated carcinoembryonic antigen level: FDG PET/CT versus contrast-enhanced 64-MDCT of the chest and abdomen.
    Metser U; You J; McSweeney S; Freeman M; Hendler A
    AJR Am J Roentgenol; 2010 Mar; 194(3):766-71. PubMed ID: 20173157
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Positron emission tomography affects surgical management in recurrent colorectal cancer patients.
    Desai DC; Zervos EE; Arnold MW; Burak WE; Mantil J; Martin EW
    Ann Surg Oncol; 2003; 10(1):59-64. PubMed ID: 12513962
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of FDG-PET in the diagnosis and treatment of colorectal liver metastases.
    Wiering B; Ruers TJ; Oyen WJ
    Expert Rev Anticancer Ther; 2004 Aug; 4(4):607-13. PubMed ID: 15270664
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The impact of fluor-18-deoxyglucose-positron emission tomography in the management of colorectal liver metastases.
    Wiering B; Krabbe PF; Jager GJ; Oyen WJ; Ruers TJ
    Cancer; 2005 Dec; 104(12):2658-70. PubMed ID: 16315241
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Colorectal cancer. Radiologic staging.
    Thoeni RF
    Radiol Clin North Am; 1997 Mar; 35(2):457-85. PubMed ID: 9087214
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The role of positron emission tomography in the management of recurrent colorectal cancer: a review.
    Watson AJ; Lolohea S; Robertson GM; Frizelle FA
    Dis Colon Rectum; 2007 Jan; 50(1):102-14. PubMed ID: 17115340
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Fluorodeoxyglucose PET/Computed Tomography on the Management of Patients with Colorectal Cancer.
    Laurens ST; Oyen WJ
    PET Clin; 2015 Jul; 10(3):345-60. PubMed ID: 26099671
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Positron emission tomography/computed tomographic scans compared to computed tomographic scans for detecting colorectal liver metastases: a systematic review.
    Patel S; McCall M; Ohinmaa A; Bigam D; Dryden DM
    Ann Surg; 2011 Apr; 253(4):666-71. PubMed ID: 21475005
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Diagnosis and treatment of colorectal liver metastases - workflow].
    Grundmann RT; Hermanek P; Merkel S; Germer CT; Grundmann RT; Hauss J; Henne-Bruns D; Herfarth K; Hermanek P; Hopt UT; Junginger T; Klar E; Klempnauer J; Knapp WH; Kraus M; Lang H; Link KH; Löhe F; Merkel S; Oldhafer KJ; Raab HR; Rau HG; Reinacher-Schick A; Ricke J; Roder J; Schäfer AO; Schlitt HJ; Schön MR; Stippel D; Tannapfel A; Tatsch K; Vogl TJ;
    Zentralbl Chir; 2008 Jun; 133(3):267-84. PubMed ID: 18563694
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Positron emission tomography and colorectal cancer.
    Arulampalam TH; Costa DC; Loizidou M; Visvikis D; Ell PJ; Taylor I
    Br J Surg; 2001 Feb; 88(2):176-89. PubMed ID: 11167864
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Positron emission tomography/computed tomography in follow-up programmes for patients with colorectal cancer].
    Hansen AF; Jensen MR; Nordholm-Carstensen A
    Ugeskr Laeger; 2016 Sep; 178(37):. PubMed ID: 27649583
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Management of recurrent colorectal cancer with positron emission tomography.
    Haji A
    Br J Hosp Med (Lond); 2007 Nov; 68(11):580-3. PubMed ID: 18087843
    [TBL] [Abstract][Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.